Morphic Holding, Inc. (MORF): Price and Financial Metrics


Morphic Holding, Inc. (MORF): $32.10

0.25 (+0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MORF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MORF POWR Grades

  • Value is the dimension where MORF ranks best; there it ranks ahead of 68.23% of US stocks.
  • MORF's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • MORF's current lowest rank is in the Growth metric (where it is better than 14.21% of US stocks).

MORF Stock Summary

  • The ratio of debt to operating expenses for MORPHIC HOLDING INC is higher than it is for about only 6.93% of US stocks.
  • MORF's price/sales ratio is 16.03; that's higher than the P/S ratio of 92.86% of US stocks.
  • As for revenue growth, note that MORF's revenue has grown 359.96% over the past 12 months; that beats the revenue growth of 97.32% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MORPHIC HOLDING INC are ARVN, IGMS, ANAB, FATE, and MRTX.
  • Visit MORF's SEC page to see the company's official filings. To visit the company's web site, go to www.morphictx.com.

MORF Valuation Summary

  • In comparison to the median Healthcare stock, MORF's price/sales ratio is 675.61% higher, now standing at 15.9.
  • MORF's price/sales ratio has moved down 38.7 over the prior 43 months.

Below are key valuation metrics over time for MORF.

Stock Date P/S P/B P/E EV/EBIT
MORF 2023-01-20 15.9 3.2 -21.1 -19.6
MORF 2023-01-19 15.5 3.1 -20.5 -19.0
MORF 2023-01-18 15.6 3.2 -20.7 -19.2
MORF 2023-01-17 16.2 3.3 -21.4 -19.9
MORF 2023-01-13 16.5 3.3 -21.8 -20.3
MORF 2023-01-12 16.5 3.4 -21.9 -20.4

MORF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MORF has a Quality Grade of C, ranking ahead of 29.24% of graded US stocks.
  • MORF's asset turnover comes in at 0.114 -- ranking 252nd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MORF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.114 1 -1.111
2021-03-31 0.150 1 -0.797
2020-12-31 0.199 1 -0.595
2020-09-30 0.170 1 -0.597
2020-06-30 0.079 1 -0.807
2020-03-31 0.072 1 -0.604

MORF Price Target

For more insight on analysts targets of MORF, see our MORF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $100.50 Average Broker Recommendation 1.4 (Strong Buy)

MORF Stock Price Chart Interactive Chart >

Price chart for MORF

MORF Price/Volume Stats

Current price $32.10 52-week high $47.66
Prev. close $31.85 52-week low $19.23
Day low $31.19 Volume 171,628
Day high $32.75 Avg. volume 264,191
50-day MA $27.86 Dividend yield N/A
200-day MA $27.34 Market Cap 1.24B

Morphic Holding, Inc. (MORF) Company Bio


Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.


MORF Latest News Stream


Event/Time News Detail
Loading, please wait...

MORF Latest Social Stream


Loading social stream, please wait...

View Full MORF Social Stream

Latest MORF News From Around the Web

Below are the latest news stories about MORPHIC HOLDING INC that investors may wish to consider to help them evaluate MORF as an investment opportunity.

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | January 13, 2023

Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST. A live webcast of the presentation will be available on the Investor section of Morphic’s

Yahoo | January 5, 2023

The Morphic Holding Inc. (MORF) had a good session last reading, didn’t it?

The share price of Morphic Holding Inc. (NASDAQ:MORF) fell to $25.81 per share on Friday from $26.44. While Morphic Holding Inc. has underperformed by -2.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MORF fell by -49.81%, with highs and lows ranging from $52.33 to $19.23, […]

US Post News | December 26, 2022

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 15, 2022

Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

First patient dosed in global study of oral α4β7 integrin inhibitorWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative colitis (UC) has commenced with the first patient receiving MORF-057. “MORF-057 offers the possibility of efficacy and tolerability through t

Yahoo | November 22, 2022

Read More 'MORF' Stories Here

MORF Price Returns

1-mo 20.00%
3-mo 8.92%
6-mo 12.24%
1-year -21.61%
3-year 59.70%
5-year N/A
YTD 20.00%
2022 -43.54%
2021 41.22%
2020 95.51%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8779 seconds.